Opinion|Videos|September 30, 2024
Translating Clinical Data Into the Practice Setting: Monotherapy and Combination Therapies in Intermediate/Poor-Risk mRCC
Author(s)Rana R. McKay, MD
Panelists discuss how the efficacy and safety profiles of various treatment options for intermediate/poor-risk metastatic renal cell carcinoma compare, including cabozantinib monotherapy, nivolumab plus cabozantinib combination, nivolumab plus ipilimumab combination, and other immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations.
Advertisement
Episodes in this series
- Please compare the efficacy and safety in the context of intermediate/poor-risk metastatic renal cell carcinoma:
- Cabozantinib monotherapy
- Nivolumab plus cabozantinib
- Nivolumab plus ipilimumab
- Other immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations
Advertisement
Related to this article
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
4
Durability of PFS and OS Benefit vs. Historical Control
5